Astellas discontinue darexaban development citing intensified competition

The oral anticoagulant market is one of the few primary care markets expected to grow significantly in the next few years, with a number of the new oral thrombin inhibitors and factor Xa inhibitors set to generate peak sales well in excess of $1billion.  … Continue reading

BI once daily combination inhaler for COPD now in phase 3

Boehringer Ingelheim (BI) recently announced that enrolment has commenced in its TOviTO Phase III clinical trial program, investigating tiotropium (Spiriva, BI/Pfizer) plus olodaterol, a long-acting beta-agonist (LABA), in a once-daily fixed-dose combination (FDC) for the treatment of chronic obstructive pulmonary disease (COPD). The company … Continue reading

Crocus derivative may be a “smart bomb” – targets tumour cells

Researchers from the Institute of Cancer Therapeutics at the University of Bradford presented preclinical data on ICT2588 at the British Science Festival in Bradford on 12 September 2011.  The drug is a vascular disrupting agent, derived from the autumn crocus (meadow saffron) … Continue reading